Concepedia

Author

Daniel Burge

Resolve Therapeutics (United States)

Also Known As

D BURGE, D Burge, D J Burge, D. Burge, Daniel Burge, Daniel J Burge, Daniel J. Burge, David Burge

33

Publications

5.1K

Citations

15

H-Index

21

Concepts

All Affiliations

Resolve Therapeutics (United States)Altoona Center for Clinical ResearchMetroplex Clinical Research CenterCenter for RheumatologyDermira (United States)
DB

About

Daniel Burge is an author at Resolve Therapeutics (United States) specializing in rheumatology, medicine, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

1.5K

2

Immunology

2

2

69

3

Allergy

1

1

41

4

Pathology

1

1

41

5

Pharmacology

1

1

28

Daniel Burge

×

16

Publications

5K

Citations

14

H-Index

YearCitations

A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate

Michael E. Weinblatt, Joel M. Kremer, Arthur D. Bankhurst,

New England Journal of Medicine

1999

2.1K

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

Philip J. Mease, Bernard S. Goffe, James M. Metz,

The Lancet

2000

1.5K

Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

Edward Keystone, Michael Schiff, Joel M. Kremer,

Arthritis & Rheumatism

2004

286

Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trial

Daniel J. Lovell, Edward H. Giannini, Andreas Reiff,

Arthritis & Rheumatism

2003

254

Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.

Larry W. Moreland, S. Cohen, Scott W. Baumgartner,

PubMed

2001

201

Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.

Phillip J. Mease, Christopher T. Ritchlin, Richard W. Martin,

PubMed

2004

156

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Alice B. Gottlieb, Andrew Blauvelt, Diamant Thaçi,

Journal of the American Academy of Dermatology

2018

151

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)

Mark Lebwohl, Andrew Blauvelt, C. Paul,

Journal of the American Academy of Dermatology

2018

129

Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observations

Joel M. Kremer, Michael E. Weinblatt, Arthur D. Bankhurst,

Arthritis & Rheumatism

2003

107

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial

James Posada, Saba Valadkhan, Daniel Burge,

Arthritis & Rheumatology

2020

58

Page 1